Skip to content

"Intra- and postoperative microbiome in pancreatic carcinoma to determine prognostic factors of postoperative morbidity and tumor recurrence" - PancBIOME

"Intra- and postoperative microbiome in pancreatic carcinoma to determine prognostic factors of postoperative morbidity and tumor recurrence" - PancBIOME - PancBIOME

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00032051
Enrollment
250
Registered
2023-06-14
Start date
2019-10-16
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical diseases of the pancreatic head, in particular pancreatic cancer.

Interventions

Group 1: Prospective collection of microbiome samples and clinical data from patients undergoing Whipple's surgery.

Sponsors

Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Ludwig-Maximilians-Universität (LMU) München
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Patients with resectable tumor of the pancreas scheduled for tumor resection, especially of the head of the pancreas, i - Ability to consent at the time of inclusion in the study - Must be of legal age at the time of admission to the study

Exclusion criteria

Exclusion criteria: - Inability to consent or underage at the time of inclusion in the study. - Mental or physical disorders that could affect informed consent or treatment - Individuals with understanding/language problems or inability to comply with study and/or follow-up procedures - Any contraindication to surgery - Acute or ongoing episode of pancreatitis (clinical symptoms of pancreatitis, elevated lipase and/or CRP levels, radiological or intraoperative signs of acute pancreatitis)

Design outcomes

Primary

MeasureTime frame
Prospective analysis of the microbiome in pancreatic head resection and its influence on subtyping, tumor growth and therapy resistance in pancreatic carcinoma.

Secondary

MeasureTime frame
30-day mortality, morbidity, length of hospital stay, initiation of systemic therapy, and oncologic outcomes in cancer patients.

Countries

Germany

Contacts

Public ContactMatthias Ilmer

Klinik für Allgemein-, Viszeral- und Transplantationschirurgie

matthias.ilmer@med.uni-muenchen.de+894400711218

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026